The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 27, 2018

Filed:

Apr. 17, 2015
Applicant:

Theraly Pharmaceuticals, Inc., Elkridge, MD (US);

Inventor:

Kang Choon Lee, Seoul, KR;

Assignee:

Theraly Pharmaceuticals, Inc., Elkridge, MD (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/19 (2006.01); A61K 47/48 (2006.01); C07K 16/28 (2006.01); A61K 38/17 (2006.01); A61K 45/06 (2006.01); C07K 14/705 (2006.01); A61K 47/60 (2017.01);
U.S. Cl.
CPC ...
A61K 38/191 (2013.01); A61K 38/177 (2013.01); A61K 45/06 (2013.01); A61K 47/60 (2017.08); C07K 14/70578 (2013.01); C07K 16/2866 (2013.01); C07K 2319/00 (2013.01); C07K 2319/73 (2013.01);
Abstract

Pro-apoptotic agents such as ligands and agonists of agonistic TRAIL receptors can induce or increase apoptosis of cells that cause fibrosis and underlying diseases such as liver, pancreatic, lung and skin diseases characterized by fibrosis, cirrhosis, or complications thereof. The compositions and methods can be used to selectively remove activated hepatic stellate cells (HSCs), the originators of liver fibrosis and cirrhosis, and activated pancreatic stellate cells (PSCs), the originators of pancreas fibrosis and pancreatitis, and can be effective to reduce or prevent further chronic fibrosis by simultaneously reducing multiple fibrosis-associated molecules secreted or induced by such activated stellate cells. The compositions are typically effective to target agonistic TRAIL receptors such as TRAIL-R1/DR4 and TRAIL-R2/DR5 that are selectively expressed in activated HSCs and PSCs in physiological conditions. Ligands and agonists that can be used to target agonistic TRAIL receptors include, but are not limited to, TRAIL-R1/DR4 and/or TRAIL-R2/DR5 agonists.


Find Patent Forward Citations

Loading…